Opsumit® Patient Enrollment and Consent Form

Complete this form for ALL patients

Fax this completed form and copies of all insurance cards (front and back) to 1-866-279-0669.

Contact Actelion Pathways™ at 1-866-228-3546 for questions.

EO1201310

1 Patient Information (please print)

First name | MI | Last name | ☐ Male ☐ Female Gender

Birth date | Primary language | Email address

Primary phone # | Alternate phone # | Best time to call

Address | City | State | ZIP

Legal guardian | Relationship | Phone #

Emergency contact | Relationship | Phone #

Certified pharmacy preference (If left blank, this referral will be sent to the appropriate certified pharmacy based on the patient's existing benefits.)

2 Actelion Pathways Services Authorization

I allow my healthcare providers and health plans to share my personal and health information about me and my Actelion therapies with Actelion and its contractors. I allow Actelion to use and share this information to: 1) establish my benefit eligibility, including benefit eligibility for laboratory services; 2) communicate with my healthcare providers, health plans, other payers, and pharmacies about my medical care; and 3) help provide any therapy access support services to me that will assist in my Actelion therapy. Actelion may leave messages for me on the telephone number(s) that I provide. These messages may state that I take an Actelion medication as well as provide me with additional information. I also allow the sharing of my health information to specific people I have identified.

I understand that Actelion does not promise to find ways to pay for my medications. I know that I am responsible for the costs of my care. I understand that once my health information has been shared with Actelion, privacy laws may no longer protect it; however, Actelion agrees to protect my information by using and sharing it only for reasons listed above or as required by law. I understand that my certified pharmacy may receive payment in connection with the use and disclosure of my information for purposes allowed under this permission. If I do not sign this form, my eligibility for health plan benefits and treatment by my healthcare provider will not change, but I will not have access to the Actelion support services. I may also cancel my permission at any time by writing a letter saying I cancel my written permission and mailing to Actelion Pharmaceuticals US, Inc.: PO Box 826, South San Francisco, CA 94083 or by faxing it to 1-866-279-0669 or by calling 1-866-228-3546. I am allowed a copy of this signed agreement. This written permission will expire 10 years after the date on which I sign it.

★ (REQUIRED FOR ALL PATIENTS) Patient or Parent/Guardian Signature | Date

3 Female Patient Agreement

For All Females: I acknowledge that I understand that Opsumit is only available through a restricted distribution program under an FDA-required Risk Evaluation and Mitigation Strategy (REMS).

For Females Who Can Get Pregnant: I acknowledge that I have been counseled on the risks of Opsumit, including the risk of serious birth defects. I have read the *Opsumit Medication Guide* and the *Opsumit REMS Guide for Females Who Can Get Pregnant*. I understand that I will be contacted by Actelion and/or its agents and contractors to receive counseling on the risk of serious birth defects, the need to use reliable contraception during Opsumit treatment and for one month after stopping Opsumit treatment, the importance of not becoming pregnant, and to ensure that I have completed pregnancy testing before I start Opsumit, monthly before each refill, and for one month after stopping Opsumit. I agree to be counseled each month by the pharmacy on the need to use reliable contraception during Opsumit treatment and for one month after stopping Opsumit. I understand that I must immediately contact my healthcare provider if I miss a menstrual period or suspect that I am pregnant; and that I may be contacted by Actelion and/or its agents and contractors to obtain information about my pregnancy, if I become pregnant.

For Pre-pubertal Females: I acknowledge that I have been counseled on the risks of Opsumit, including the risk of serious birth defects, and that I have read the *Opsumit Medication Guide*. I understand that I must immediately contact my healthcare provider if I get my menstrual period.

For Post-menopausal Females: I acknowledge that I have received and read the *Opsumit Medication Guide*.

★ (REQUIRED FOR ALL FEMALES) Patient or Parent/Guardian Signature | Date

4 Prescriber Information

First name | Middle initial

Last name

Address | City

State | ZIP | Phone #

Fax | NPI #

Opsumit ID

Office contact and email address

5 Diagnosis, Prescription, and Shipping Information

(Check ONLY ONE Box for the Diagnosis Related to Opsumit Treatment)

Pulmonary Arterial Hypertension (PAH)

☐ Idiopathic PAH ☐ Heritable PAH ☐ Connective Tissue Disorder ☐ Congenital Heart Disease

☐ Other

Opsumit (macitentan) dosing: 10 mg tablet(s) NDC66215-501-30

_____ Time(s) daily Quantity: _____ Refills: _____

Instructions for use:

Ship to: ☐ Patient home ☐ Prescriber office ☐ Other

Address

City | State | ZIP

6 Prescriber Authorization

If your patient is FEMALE, check correct female patient category (please see definitions of these terms on the following page):

REQUIRED (Check one box)

Female of Reproductive Potential

If this patient is a Female of Reproductive Potential, has a negative pregnancy test been completed prior to prescribing Opsumit?

☐ Yes ☐ No

Female of Non-Reproductive Potential

☐ **Pre-pubertal Female** ☐ **Post-menopausal Female**

I certify that the above therapy is medically necessary and agree to follow the "Prescriber Requirements" indicated on the second page of this form.

★ (REQUIRED FOR ALL PRESCRIBERS) Prescriber signature | Date

Definitions of Reproductive Potential Status

Females of Reproductive Potential

Females of Reproductive Potential include girls who have entered puberty and all females who have a uterus and have not passed through menopause (as defined below).

For the purposes of this REMS, puberty includes those girls who are at least Tanner Stage 3 and have not yet had a menses (premenarchal).

Females of Non-Reproductive Potential

Pre-pubertal Females: Females who are at Tanner Stages 1 and 2 are not considered to be of reproductive potential.

Post-menopausal Female: Females who have passed through menopause (as defined below).

Definition of Menopause

Menopause is defined as 12 months of spontaneous amenorrhea (not amenorrhea induced by a medical condition or medical therapy) or post-surgical form bilateral oophorectomy.

Prescriber Requirements

For All Females

- I acknowledge that I have counseled the patient (and parent/guardian when appropriate) that Opsumit is only available through a restricted distribution program under an FDA-required REMS
- I will evaluate the patient and agree to document any change in reproductive potential status by submitting a *Opsumit REMS Reproductive Potential Status Form* within 10 business days of becoming aware of the change

For Females of Reproductive Potential

- I acknowledge that I have counseled the patient (and parent/guardian when appropriate) on the risks of Opsumit, including the risk of serious birth defects, and that I have reviewed the *Opsumit Medication Guide* and the *Opsumit REMS Guide for Females Who Can Get Pregnant* with the patient (and parent/guardian when appropriate)
- I will order and review pregnancy tests prior to initiation of Opsumit treatment, monthly during treatment, and for 1 month after stopping treatment in accordance with the Opsumit REMS Program

For Pre-pubertal Females

- I acknowledge that I have counseled the patient and parent/guardian on the risks of Opsumit, including the risk of serious birth defects, and that I have reviewed the *Opsumit Medication Guide* with the patient and parent/guardian
- I will evaluate the patient's reproductive potential status, verify reproductive potential status annually for Pre-pubertal Females who are at least 8 years of age and older, and agree to report any change in reproductive potential status on a *Opsumit REMS Reproductive Potential Status Form* within 10 business days of becoming aware of the change

7 Fax this form to 1-866-279-0669

Please visit www.OpsumitREMS.com or call 1-866-ACTELION (1-866-228-3546) for more information about the Opsumit REMS Program.